Danny Shearer, MD
Gastroenterology · Washington, DCNPI 1275594905
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,707 of the $10,848 with a category attached, or 80.3%. It is spread thinly across 28 manufacturers, the largest accounting for just 19.1% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $3,587, 6.3 times the $569 reported in 2019.
Across 447 payments — averaging $24.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pentax Of America, Inc.$2K
- AbbVie$2K
- Johnson & Johnson$2K
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$1K
- Ardelyx, Inc.$577
- Ironwood Pharmaceuticals, Inc$515
- plus $3K from 22 others
What the payments were for
- Food & beverage$8,70780%
- Education$711%
- Other$2,06919%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pentax Of America, Inc. | 2 | $2,069 |
| AbbVie(2 entities) | 97 | $2,034 |
| Johnson & Johnson | 82 | $1,584 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 79 | $1,457 |
| Ardelyx, Inc. | 26 | $577 |
| Ironwood Pharmaceuticals, Inc | 28 | $515 |
| Bristol Myers Squibb | 29 | $395 |
| Intercept Pharmaceuticals, Inc. | 13 | $333 |
| Takeda Pharmaceuticals U.S.A., Inc. | 15 | $295 |
| QOL Medical, LLC | 11 | $239 |
| Gilead | 15 | $228 |
| Regeneron Healthcare Solutions, Inc. | 10 | $187 |
| Ferring Pharmaceuticals Inc. | 7 | $155 |
| Echosens North America, Inc. | 1 | $117 |
| Phathom Pharmaceuticals, Inc. | 6 | $107 |
| Braintree Laboratories, Inc. | 4 | $98 |
| Ipsen Biopharmaceuticals, Inc | 3 | $71 |
| Pfizer | 3 | $69 |
| Madrigal Pharmaceuticals | 2 | $61 |
| UCB, Inc. | 2 | $46 |
| Evoke Pharma, Inc. | 3 | $46 |
| E.r. Squibb & Sons, L.L.C. | 2 | $44 |
| Aimmune Therapeutics, Inc. | 2 | $36 |
| Celltrion USA Inc. | 1 | $30 |
| W. L. Gore & Associates, Inc. | 1 | $15 |
| Novo Nordisk | 1 | $15 |
| Sanofi | 1 | $14 |
| Olympus America Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- PENTAX Medical$2,069
- FibroScan$117
How this compares
$10,848 in reported general payments places this provider in the 80th percentile of 77 gastroenterology providers in District of Columbia.
See all gastroenterology providers in District of Columbia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LinzessLinaclotide | 132 | $175,365 |
| TrulancePlecanatide | 20 | $29,385 |
| Mesalamine | 28 | $13,948 |
| Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates | 133 | $7,371 |
| Lubiprostone | 49 | $7,180 |
| Famotidine | 249 | $4,936 |
| Esomeprazole Magnesium | 64 | $3,288 |
| Cimetidine | 34 | $2,917 |
| Sucralfate | 31 | $2,724 |
| Gavilyte-GPeg3350/Sod Sulf,bicarb,cl/Kcl | 85 | $1,298 |
| Pantoprazole Sodium | 88 | $1,122 |
| Dicyclomine Hcl | 45 | $788 |
| Omeprazole | 33 | $534 |
| Lactulose | 40 | $458 |
| Peg-3350 And ElectrolytesPeg3350/Sod Sulf,bicarb,cl/Kcl | 20 | $353 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLinzess | $2,034 | $175,365132 claims |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance | $1,457 | $29,38520 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 77 gastroenterology providers in District of Columbia.
Other gastroenterology in Washington
- James LewisWashington$1M
- John HoganWashington$354K
- Mark MattarWashington$349K
- Jessica KormanWashington$171K
- Mitesh PatelWashington$90K
- Sumona BhattacharyaWashington$87K
- Roshan BashirWashington$40K
- Bruce LuxonWashington$37K
- Lauren GeorgeWashington$32K
- Dominique HowardWashington$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.